U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C36H39N3O6.ClH
Molecular Weight 646.172
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of NIGULDIPINE HYDROCHLORIDE, (±)-

SMILES

Cl.COC(=O)C1=C(C)NC(C)=C(C1C2=CC(=CC=C2)[N+]([O-])=O)C(=O)OCCCN3CCC(CC3)(C4=CC=CC=C4)C5=CC=CC=C5

InChI

InChIKey=MHOSUIMBPQVOEU-UHFFFAOYSA-N
InChI=1S/C36H39N3O6.ClH/c1-25-31(34(40)44-3)33(27-12-10-17-30(24-27)39(42)43)32(26(2)37-25)35(41)45-23-11-20-38-21-18-36(19-22-38,28-13-6-4-7-14-28)29-15-8-5-9-16-29;/h4-10,12-17,24,33,37H,11,18-23H2,1-3H3;1H

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C36H39N3O6
Molecular Weight 609.7114
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description

Niguldipine, a mixture of two forms: (-) and (+)-Niguldipine is an antagonist of alpha 1A adrenoreceptors. Preclinical studies of niguldipine as an anticonvulsive drug on mice was revealed that the use of niguldipine in epileptic patients seems questionable.

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct

PubMed

Sample Use Guides

In Vivo Use Guide
in mice: niguldipine (up to 2.5 mg/kg) did not influence the electroconvulsive threshold in mice, although a higher dose of niguldipine (5 mg/kg) significantly elevated it.
Route of Administration: Oral
In Vitro Use Guide
The effect of increasing concentrations of daunomycin on the inhibition of cell growth in MCF-7/adr cells was examined in the absence and presence of the 4-aryl-1,4-dihydropyridines (Ia-q) and 4-arylpyridines (IIa-q). The control studies were performed using the vehicle (0.1% DMSO), whereas niguldipine (3 μM) served as a positive control. All of the compounds that significantly increased vinblastine accumulation were able to significantly decrease the IC50 values of daunomycin. If, Ih1, and Ih2, which did not affect drug accumulation, also did not lower the IC50 of daunomycin when compared with the control.
Substance Class Chemical
Record UNII
5QC11TLQ7K
Record Status Validated (UNII)
Record Version